# HitGen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hitgen

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.hitgen.com/
- Total disclosed funding: $39M
- Latest round: Series B (May 28, 2018)
- Investors on record: 6

## About

Founded in 2012 and based in Chengdu, China, HitGen Inc., also known as Chengdu Pioneer Drug Development Co., Ltd., develops technology platforms for the discovery and optimization of small molecules and nucleic acid based therapeutics. The company operates subsidiaries in Cambridge in the United Kingdom and Houston in the United States. In April 2020, HitGen completed an IPO on the Shanghai Stock Exchange under the ticker "688222".

The company works with pharmaceutical and biotechnology organizations to provide drug discovery platforms including DNA encoded library technology, fragment based discovery, structure based design, and tools for nucleic acid based therapeutics. 

The company generates revenue through collaboration agreements, research service contracts and licensing of its drug discovery platforms.

Following its IPO, HitGen Inc. plans to advance technologies that support the discovery and optimization of small molecule and nucleic acid based therapeutics.

## Funding rounds

- Series B, May 28, 2018, $39M — CDH Investments, Leadyond Capital
- Series A, Jul 25, 2016 — Yanyuan Venture Capital, Shiyu Capital, Chongqing Boyi Equity Investment Fund Management
- Angel, Jun 23, 2015 — CS Venture

## Investors

- CS Venture (https://capitalatlas.ai/funds/cs-venture) — Angel
- Yanyuan Venture Capital — Series A
- Shiyu Capital (https://capitalatlas.ai/funds/shiyu-capital) — Series A
- Chongqing Boyi Equity Investment Fund Management — Series A
- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Series B
- Leadyond Capital (https://capitalatlas.ai/funds/leadyond-capital) — Series B